Methods and systems for genetic analysis
This disclosure provides systems and methods for sample processing and data analysis. Sample processing may include nucleic acid sample processing and subsequent sequencing. Some or all of a nucleic acid sample may be sequenced to provide sequence information, which may be stored or otherwise maintained in an electronic storage location. The sequence information may be analyzed with the aid of a computer processor, and the analyzed sequence information may be stored in an electronic storage location that may include a pool or collection of sequence information and analyzed sequence information generated from the nucleic acid sample. Methods and systems of the present disclosure can be used, for example, for the analysis of a nucleic acid sample, for producing one or more libraries, and for producing biomedical reports. Methods and systems of the disclosure can aid in the diagnosis, monitoring, treatment, and prevention of one or more diseases and conditions.
1. A method for sequencing a nucleic acid sample isolated from a body fluid of an individual, comprising:
(a) contacting said nucleic acid sample with one or more capture probe sets to produce one or more capture probe hybridized nucleic acid molecules, wherein said one or more capture probe sets are configured to selectively enrich for an exome, wherein said exome comprises:
(i) exons,
(ii) untranslated regions (UTRs), and
(iii) one or more splice sites, one or more intronic regions, one or more regulatory regions, or a combination thereof; and
(b) conducting one or more sequencing reactions on said one or more capture probe hybridized nucleic acid molecules to produce at least 1,000,000,000 sequencing reads.
2. The method of claim 1 , wherein said one or more sequencing reads comprise paired end reads of at least 2×150 nucleotides.
3. The method of claim 1 , wherein said one or more regulatory regions comprise regulatory regions identified in a Regulome database.
4. The method of claim 3 , wherein said regulatory regions comprise non-coding regulatory regions.
5. The method of claim 4 , wherein said non-coding regulatory regions comprise regulatory elements located in 5′ or 3′ untranslated regions.
6. The method of claim 4 , wherein said non-coding regulatory regions comprise regulatory elements located within introns.
7. The method of claim 1 , wherein said capture probe set configured to selectively enrich for said exome comprises sequences configured to capture genomic region features.
8. The method of claim 7 , wherein said genomic region features comprise gene phasing and reassembly genes.
9. The method of claim 8 , wherein said gene phasing and reassembly genes comprise one or more major histocompatibility complexes.
10. The method of claim 1 , wherein said one or more capture probe sets additionally comprise capture probes that are configured to selectively enrich for pathogen derived nucleic acid molecules.
11. The method of claim 1 , wherein said one or more capture probe sets further comprises barcodes.
12. The method of claim 1 , wherein said body fluid of said subject is selected from the group consisting of: blood, plasma, serum, saliva, sputum, semen, transvaginal fluid, cerebrospinal fluid, and any combination thereof.
13. The method of claim 12 , wherein said body fluid is plasma.
14. A method for sequencing a nucleic acid sample isolated from a bodily fluid of an individual to determine a presence or absence of cancer, comprising
(a) producing, with the aid of a computer processor, one or more capture probes, wherein said one or more capture probes are configured to hybridize to one or more genomic features selected from the group consisting of exons, untranslated regions (UTRs), splice sites, intronic regions and regulatory regions;
(b) contacting said nucleic acid sample with said one or more capture probes to produce one or more capture probe hybridized nucleic acid molecules, wherein said one or more capture probes selectively enriches for an exome; and
(c) conducting one or more sequencing reactions on said one or more capture probe hybridized nucleic acid molecules to produce at least 1,000,000,000 sequencing reads.